Padua RA, Beurlet S, Krief P, Omidvar N, Pogam CL, Auboeuf D, le la Grange P, Soulie A, Janin A, M-E N, Merlet P, Sarda-Mantel L, Fenaux P, Konopleva M, Andreeff M , Tu A, Yang P, Fan AC, Kogan SC, Weissman IL, Felsher DW, Pla M, West R, Chomienne C
It reflects what experienced users report as effective
Enfermedad heptica: ambos frmacos podran reducir el riesgo Los pacientes con diabetes tipo 2 y enfermedad heptica crnica que tomaron GLP-1 tuvieron un riesgo reducido de desarrollar cncer de hgado y cirrosis (cicatrizacin del hgado) en comparacin con aquellos que no tomaron el medicamento, encontr un estudio intestinal
PMID:25716148
The FDA labels for GLP-1 medications list a higher chance of gallstones and gallbladder disease as a potential risk
The blood samples were diluted 1:2 in phosphate-buffered saline (PBS), layered onto a separation solution (Biocoll 1.077 g/ml, Biochrom AG, Berlin, Germany), and centrifuged (800 x g, 20 min, 20C, Multifuge X3 F2, Thermo Fisher Scientific, Dreieich, Germany)